论文部分内容阅读
目的研究血清ＣＡ１２５对肝癌的诊断价值．方法肝癌患者３２例，男２０例，女１２例，平均年龄４６岁±２５岁；肝硬变３６例，男２７例，女９例，平均年龄４２岁±２３岁；正常对照组４０例．全部受测对象均静脉采血，分离血清，－２０℃贮存备测．采用ＩＲＭＡ法测定血清ＣＡ１２５含量．结果肝癌患者血清ＣＡ１２５含量２１８Ｕ／Ｌ±１３０Ｕ／Ｌ，显著高于肝硬变组和正常对照组（分别为１９Ｕ／Ｌ±１１Ｕ／Ｌ，１０Ｕ／Ｌ±８Ｕ／Ｌ，Ｐ＜００１）．肝硬变组高于正常对照（Ｐ＜００５），但显著低于肝癌组（Ｐ＜００１）．以２６Ｕ／Ｌ为界限值，肝癌阳性检出率为６８７％，其中ＡＦＰ阳性（ＡＦＰ＞４００μｇ／Ｌ）的肝癌中血清ＣＡ１２５的阳性检出率为７６０％，ＡＦＰ阴性（ＡＦＰ＜２０μｇ／Ｌ）的肝癌中血清ＣＡ１２５的阳性检出率为４２９％．结论血清ＣＡ１２５是诊断肝癌较好的肿瘤标记物
4. Objective To study the diagnostic value of serum CA125 in liver cancer. Methods 32 cases of liver cancer patients, 20 males and 12 females, mean age 46 years ± 25 years old; cirrhosis in 36 cases, 27 males and 9 females, mean age 42 years ± 23 years old; normal control group of 40 cases. All subjects were intravenously collected blood, serum was separated, and stored at -20°C for testing. IRMA method was used to determine serum CA125 content. Results The serum CA125 level of liver cancer patients was 218U/L±130U/L, which was significantly higher than that of cirrhosis group and normal control group (19U/L±11U/L, 10U/L±8U/L, P<001, respectively). . The cirrhosis group was higher than the normal control (P<005), but significantly lower than the liver cancer group (P<001). With a limit of 26 U/L, the positive detection rate of liver cancer was 68.7%, of which the positive detection rate of serum CA125 in AFP-positive (AFP>400 μg/L) was 76.0%, and AFP was negative (AFP< The positive detection rate of serum CA125 was 209% in the liver cancer of 20μg/L). Conclusion Serum CA125 is a better tumor marker for diagnosis of liver cancer